China's RatingDog Services PMI for October was 52.6, compared to 52.9 in the previous month.

Shenzhen Huaqiang: The company currently does not hold any equity in BYD Semiconductor, but maintains a long-term and stable business partnership with BYD Semiconductor.

Key News 1. 2.3099 million new A-share accounts were opened in October, bringing the cumulative total for the first 10 months to 22.4588 million, a year-on-year increase of 11%. 2. The People's Bank of China: It will conduct 700 billion yuan of outright reverse repurchase operations on November 5th, with a term of 3 months (91 days). Individual Stock News 1. Midea Group: Has cumulatively paid 9.575 billion yuan to repurchase A-shares. 2. Foxconn Industrial Internet: As of October 31st, it had cumulatively repurchased 0.04% of its shares, amounting to 147 million yuan. 3. Fuyao Glass: The legal representative of the company has changed from Cao Dewang to his son, Cao Hui. 4. Mi Holdings: The seal for the cooling salt circulation pump has been applied to the Gansu thorium-based nuclear reactor project. 5. Zhongjing Technology's third-largest shareholder, LONGi Green Energy, and director Guo Bingjian plan to reduce their holdings by no more than 3.66% in total. 6. Redick: Plans to acquire a 20.41% stake in Aoyi Technology, a robotics and brain-computer interface company, for RMB 160 million. 7. China Cinda, the third largest shareholder of Founder Securities, plans to reduce its holdings in the company by no more than 1%. 8. Trina Solar: Signed a memorandum of understanding with Pacific Green for a 5GWh grid-scale battery energy storage system. 9. Baili Tianheng: Its innovative biological drug T-Bren (HER2ADC) has been included in the list of breakthrough therapies. 10. Baose: Not involved in the 2MWt liquid fuel thorium-based molten salt experimental reactor (TMSR-LF1) project reported by the media. 11. Hailu Heavy Industry: The safety dedicated device for the 2MWt liquid fuel thorium-based molten salt experimental reactor manufactured by the company passed the acceptance review by the expert group of the Chinese Academy of Sciences. 12. Lanzhou Petrochemical Equipment: Only microchannel heat exchangers and plate heat exchangers in the company's business have relevant applications in the field of controlled nuclear fusion. 13. Tianpu Pharmaceutical: The share transfer agreement signed between the controlling shareholder and its concerted parties and Zhonghao Xinying has been completed. 14. Haichuang Pharmaceutical: The first batch of participants have been enrolled in the Phase II clinical trial of its drug HP515 for the treatment of metabolic-related steatohepatitis. Currently, there are no similar target products approved for marketing in China.